Evidence map›Paper›PMID 40143395›Full record

ArticleCurrent computer-aided drug design2026

Prediction Factors for Quality Risks in the Pharmaceutical Development of Tablets Bisoprolol Fumarate with Indapamide.

Nadia Malanchuk, Mariana Demchuk, Andriy Sverstiuk, Yuri Palaniza

Abstract read
PubMed Publisher
In one paragraph

Article in Current computer-aided drug design, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Nadia MalanchukDepartment of Pharmacy Management, Economics and Technology I.Horbachevsky Ternopil National Medical University, Ternopil, Ukraine.ORCID 0000-0002-0175-7502
Mariana DemchukDepartment of Pharmacy Management, Economics and Technology I.Horbachevsky Ternopil National Medical University, Ternopil, Ukraine.ORCID 0000-0002-9105-2302
Andriy SverstiukDepartment of Medical Informatics I.Horbachevsky Ternopil National Medical University, Ternopil, Ukraine.ORCID 0000-0001-8644-0776
Yuri PalanizaDepartment of Radio Engineering Systems Ternopil National Ivan Puluj Technical University, Ternopil, Ukraine.ORCID 0000-0002-8710-953X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAn important characteristic of the quality-by-design approach is defining risk, which is a combination of the probability of harm and its severity. During risk assessment, it is essential to determine how the formulation, properties of active ingredients and excipients, and process parameters can potentially affect critical quality attributes or critical process parameters.

objectiveto develop an algorithm and a mathematical model for predicting quality risks in the pharmaceutical development of bisoprolol fumarate tablets with indapamide.

methodsThe software programs "Microsoft Excel 2016" and "Statistica 10.0" (StatSoft, Inc.) were used to predict potential risks and to build a regression model of quality-related risks for bisoprolol fumarate tablets with indapamide. RESULTS AND DISCUSSION: A mathematical model for predicting the tablet quality risk has been developed, incorporating significant predictors: Carr's index for powder mixtures (Х1), evaluation of the pressing process (Х2), uniformity of tablet weight (Х3), tablets hardness testing (Х4), disintegration time (Х6). Four levels of quality risk are defined: low risk [0.8-1.0], moderate risk [0.6-0.8], high risk [0.4-0.6], and critical risk [0-0.4]. The calculated coefficient of determination of the forecasting model (R

conclusionThe developed algorithm and mathematical model for predicting tablet quality risks are highly informative and qualitative. The proposed approach represents an innovative and promising tool for assessing and predicting risks associated with the quality of medicinal products, particularly during the early stages of pharmaceutical development.

Indexed as

BisoprololDrug DevelopmentIndapamideAlgorithmsChemistry, PharmaceuticalExcipientsModels, TheoreticalPrediction AlgorithmsRisk AssessmentTabletsBisoprololExcipientsIndapamideTabletsbisoprolol fumarateindapamidemathematical modelpharmaceutical developmentPrediction factorsquality risksregression modeltablets

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.